ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.81
-0.51%
US Tech 100
18,981.20
0.38%
S&P 500
5,629.32
0.26%
US Dollar vs CAD
1.44626
0.22%
Bitcoin
83,396.18
6.28%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Krystal Biotech Inc (KRYS) Share Price

Krystal Biotech Inc

Krystal Biotech Inc (KRYS)

NASDAQ
184.02
0.27
( 0.15% )
Updated: 13:38:45
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
184.02
Bid
183.92
Ask
184.57
Volume
205,284
179.33 Day's Range 186.95
141.72 52 Week Range 219.34
Market Cap
5.301B
Previous Close
183.75
Open
184.50
Last Trade
1
@
184.3307
Last Trade Time
13:38:55
Financial Volume
US$ 37,386,669
VWAP
182.1217
Average Volume (3m)
271,599
Shares Outstanding
28,806,078
Dividend Yield
-
PE Ratio
58.83
Earnings Per Share (EPS)
3.1
Revenue
290.52M
Net Profit
89.16M

About Krystal Biotech Inc

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.krystalbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was US$183.75. Over the last year, Krystal Biotech shares have traded in a share price range of US$ 141.72 to US$ 219.34.

Krystal Biotech currently has 28,806,078 shares outstanding. The market capitalization of Krystal Biotech is US$5.29 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 58.83.

Ask ADVFN Intelligence (AI)

Krystal Biotech (KRYS) Options Flow Summary

KRYS Options Flow

Overall Flow

Bullish

Net Premium

35k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

KRYS Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 28 2025
KRYS (0.15%)

Form 8-K - Current report
Edgar (US Regulatory)
February 28 2025
KRYS (0.15%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 27 2025
KRYS (0.15%)

Form 8-K - Current report
Edgar (US Regulatory)
February 19 2025
KRYS (0.15%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
February 19 2025
KRYS (0.15%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
113.587.96761323633170.44186.95167.5401282829179.73032899CS
431.6720.7876599934152.35190146301507174.48782735CS
1216.5559.88564774729167.465190141.72271599163.51577675CS
26-1.32-0.712204596957185.34207.84141.72256713173.35498853CS
5211.976.95727986051172.05219.34141.72297056176.09663047CS
156117.58176.97170379366.44219.3447.67262937128.25182222CS
260130.57244.28437792353.45219.3433.0848230987106.31850087CS

KRYS - Frequently Asked Questions (FAQ)

What is the current Krystal Biotech share price?
The current share price of Krystal Biotech is US$ 184.02
How many Krystal Biotech shares are in issue?
Krystal Biotech has 28,806,078 shares in issue
What is the market cap of Krystal Biotech?
The market capitalisation of Krystal Biotech is USD 5.29B
What is the 1 year trading range for Krystal Biotech share price?
Krystal Biotech has traded in the range of US$ 141.72 to US$ 219.34 during the past year
What is the PE ratio of Krystal Biotech?
The price to earnings ratio of Krystal Biotech is 58.83
What is the cash to sales ratio of Krystal Biotech?
The cash to sales ratio of Krystal Biotech is 18.05
What is the reporting currency for Krystal Biotech?
Krystal Biotech reports financial results in USD
What is the latest annual turnover for Krystal Biotech?
The latest annual turnover of Krystal Biotech is USD 290.52M
What is the latest annual profit for Krystal Biotech?
The latest annual profit of Krystal Biotech is USD 89.16M
What is the registered address of Krystal Biotech?
The registered address for Krystal Biotech is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Krystal Biotech website address?
The website address for Krystal Biotech is www.krystalbio.com
Which industry sector does Krystal Biotech operate in?
Krystal Biotech operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RAYRaytech Holding Ltd
US$ 1.741
(100.11%)
92.65M
SYRSSyros Pharmaceuticals Inc
US$ 0.166
(81.22%)
663.61M
TSVT2seventy bio Inc
US$ 4.95
(76.79%)
29.65M
SPHLSpringview Holdings Ltd
US$ 6.16
(50.98%)
962.47k
TNONTenon Medical Inc
US$ 1.85
(48.00%)
33.59M
WCTWellchange Holdings Company Limited
US$ 0.6766
(-73.04%)
31.13M
ARVNArvinas Inc
US$ 8.5962
(-51.05%)
14M
LZMHLZ Technology Holdings Ltd
US$ 7.925
(-49.39%)
586.44k
SPGCSacks Parente Golf Inc
US$ 0.1039
(-35.10%)
32M
HTCOHigh Trend International Group
US$ 1.61
(-24.41%)
150.27k
SYRSSyros Pharmaceuticals Inc
US$ 0.1659
(81.11%)
663.64M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0383
(14.33%)
390.27M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 8.0408
(8.95%)
258.96M
NVDANVIDIA Corporation
US$ 110.15
(2.96%)
258.75M
CUTRCutera Inc
US$ 0.1088
(-15.33%)
210.1M

KRYS Discussion

View Posts
Monksdream Monksdream 4 months ago
KRYS. Under $200
👍️0
Monksdream Monksdream 7 months ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 10 months ago
KRYS 10Q due 5/6
👍️0
Monksdream Monksdream 11 months ago
KRYS over $30
👍️0
Monksdream Monksdream 1 year ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 2 years ago
From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
👍️0
wiredawg wiredawg 3 years ago
Moving nicely today...
👍️0
wiredawg wiredawg 3 years ago
Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
👍️0
wiredawg wiredawg 3 years ago
In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

👍️0
wiredawg wiredawg 3 years ago
30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
👍️0
wiredawg wiredawg 3 years ago
This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
👍️0
wiredawg wiredawg 3 years ago
Holding well so far, why the pretty hard drop?
👍️0
wiredawg wiredawg 3 years ago
Why are you surprised? Serious question, not being impudent...
👍️0
rynlrt rynlrt 3 years ago
200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
👍️0
Fofo812 Fofo812 3 years ago
Surprised it held up this long
👍️0
crudeoil24 crudeoil24 3 years ago
Large tutes holdings. Some taking huge gains before years end.
👍️0
rynlrt rynlrt 3 years ago
Not sure this kind of gain is sustainable. May see a big pullback
👍️0
Fofo812 Fofo812 3 years ago
3rd post
👍️0
crudeoil24 crudeoil24 3 years ago
Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
👍️0
Trophy Trophy 5 years ago
..
👍️0

Your Recent History

NASDAQ
KRYS
Krystal Biotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads